SWTX SpringWorks Therapeutics
- 41.430
- +0.540+1.32%
- 41.150
- -0.280-0.68%
SpringWorks Therapeutics News
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue n
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announ
HC Wainwright & Co. : The SpringWorks Therapeutics (SWTX.US) rating was confirmed and adjusted from buy to buy, with a target price of $74.00.
HC Wainwright & Co. : The SpringWorks Therapeutics (SWTX.US) rating was confirmed and adjusted from buy to buy, with a target price of $74.00.
HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics with a Buy and maintains $74 price target.
SpringWorks Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 64.04% HC Wainwright & Co. → $74 Reiterates Buy → Buy 03/06/2024 66.26% JP Morgan $74 → $75 Mai
Analysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)
Earnings Call Summary | SpringWorks Therapeutics(SWTX.US) Q1 2024 Earnings Conference
The following is a summary of the SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript:Financial Performance:SpringWorks Therapeutics reported revenue of $21 million after the succes
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating
SpringWorks Therapeutics (SWTX) has an average rating of buy and price targets ranging from $58 to $80, according to analysts polled by Capital IQ. Price: 43.54, Change: -3.30, Percent Change: -7.05
SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
Buy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising Pipeline
SpringWorks Therapeutics Cash, Cash Equivalents and Marketable Securities Were $573M as of March 31 >SWTX
SpringWorks Therapeutics Cash, Cash Equivalents and Marketable Securities Were $573M as of March 31 >SWTX
SpringWorks Therapeutics Q1 2024 GAAP EPS $(1.18) Misses $(1.16) Estimate, Sales $21.006M Beat $12.206M Estimate
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.16) by 1.72 percent. This is unchanged from the same period las
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, Vs. Street Est of $13.1M
06:31 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M
SpringWorks Therapeutics 1Q Loss $87.4M >SWTX
SpringWorks Therapeutics 1Q Loss $87.4M >SWTX
SpringWorks Therapeutics 1Q Loss/Shr $1.18 >SWTX
SpringWorks Therapeutics 1Q Loss/Shr $1.18 >SWTX
Springworks Therapeutics (SWTX) Receives a Buy From Barclays
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Correction to SpringWorks Therapeutics Rating on March 6
JP Morgan raised its price target on SpringWorks to $75.00/share from $74.00/share. "SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by JP Morgan" at 6:49 a.m. ET on March 6 i
Analysis
Price Target
No Data
